2023
Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with a Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma
Stockton S, Dan A, Cecchini M, Ajumaily R, Whisenant J, Gore S, Ivy P, LoRusso P, Berlin J, Das S. Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with a Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma. Endocrine Abstracts 2023 DOI: 10.1530/endoabs.89.t1.Peer-Reviewed Original Research
2007
A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358
Spear M, LoRusso P, Tolcher A, Lin C, Wang D, Heath E, Lloyd G, Cropp G, Papadopoulos K. A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358. Journal Of Clinical Oncology 2007, 25: 14097-14097. DOI: 10.1200/jco.2007.25.18_suppl.14097.Peer-Reviewed Original ResearchStable diseaseAdverse eventsDrug accumulationGrade 2 adverse eventsMultiple murine tumor modelsDose-escalation studyDose-limiting toxicityObserved adverse eventsPhase 1 studyTumor vascular endothelial cellsDirect cytotoxic activityMurine tumor modelsVascular endothelial cellsTumor vascular collapseEscalation studyFirst doseDose escalationSafety profileEfficacious dosePreclinical dataTumor regressionPancreatic adenocarcinomaAverage CmaxVascular collapsePK data